patients with multiple endocrine neoplasias Type I explored in the Royal Hobart Hospital in 1984, adenomata or hyperplasia were identified in 33 parathyroid glands and in every case, without exception, these were clearly demonstrated by the blue staining resulting from the infusion administered some 45 minutes prior to gland exposure.
Methylene blue is a redox reagent existing in two forms, oxidised (methylene blue) and reduced (colourless leucomethylene blue). At physiological Pa02 methylene blue appears to have mildly oxidative properties and in high concentrations methylene blue may oxidise the ferrous iron of oxyhaemoglobin to the ferric form producing methaemoglobinaemia. Significant concentrations of methaemoglobin have been reported in one case study where methylene blue was infused to aid in the identification of a pancreatic adenoma. 5 A more familiar use of methylene blue paradoxically is to assist in the treatment of methaemoglobinaemia. In this situation methylene blue acts as a catalyst promoting the subsidiary salvage pathway for reconversion of methaemoglobin to oxyhaemoglobin using the white cell diaphorase NADP system.
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The present study was designed to determine the plasma concentrations of methylene blue and the level of methaemoglobin production during infusion of patients undergoing parathyroid adenoma surgery. The study was undertaken to establish whether significant methaemoglobin concentrations were generated during methylene blue infusions and whether these concentrations could be related to the corresponding methylene blue concentration.
MATERIALS AND METHODS
All patients were informed of the nature of the investigation during the routine preoperative visit, and consent obtained for withdrawal of venous samples for methylene blue and methaemoglobin estimation.
The patients were premedicated with either papaveretum and hyoscine, or pethidine and atropine (promethazine occasionally being used in place of atropine), in a dose appropriate to their weight, and was administered intramuscularly, no later than 90 minutes prior to surgery.
Anaesthesia was introduced with either thiopentone or methohexitone, in the appropriate dosage, followed by the inhalation of 66070 nitrous oxide and oxygen 33070, supplemented by a volatile agent. ECG, pulse rate and blood pressure were monitored throughout the procedure. Two 16-gauge Teflon catheters were inserted into peripheral veins, one for the infusion of methylene blue, and the other, in the opposite arm, permitting the withdrawal of venous blood for analytical purposes.
Methylene blue (5 mg/kg) was prepared as a 500 ml infusion solution containing 4070 dextrose and 0.18070 sodium chloride on the morning of the operation and infused via either an infusion set (Travenol) or infusion pump (Oximetric) as outlined in Table 1 . Blood samples (6 ml) were taken prior to infusion, at intervals during the infusion and after the infusion had ceased. The blood was collected into 10 ml plastic tubes containing 1.5 ml citrate dextrose and 30 mg sodium fluoride. 7 The whole blood assay of DiSanto and Wagner 8 was used to quantify the concentrations of methylene blue in blood. The percentage methaemoglobin in the blood sample was quantified by the cyanide method 9 as this particular assay is not affected by the presence of methylene blue. 6 A nonionic detergent solution (Nonidet P40) was included to minimise turbidity in the haemolysate.
Pharmacokinetic parameters for methylene The pharmacokinetic data derived for all patients is shown in Table 2 . Considerable variability in both the concentrations (as reflected by the AUC and Cmax) of methylene blue and methaemoglobin is observed between the patients. In contrast, the mean residence times of methylene blue and methaemoglobin (despite the inherent inaccuracies in their estimation) are less variable. No apparent correlation existed between the extent of methaemoglobin production and the methylene blue concentrations (Cmas and AUC) found in the patients. As the arterial blood gas tensions of all patients were within acceptable limits (Table 2) , the methaemoglobin produced on methylene blue infusion did not appear to significantly The rapid decline in methylene blue concentrations on cessation of infusion may be important in relation to methaemoglobin production. This production is only likely to be of significance during infusion when methylene blue concentrations are high. Although the time course of methaemoglobin production parallels that for the methylene blue concentrations (Figure 1 ), no apparent relationship exists between the methaemoglobin production and methylene blue concentrations found in the patients ( Table 2 ). The variability in methaemoglobin production is therefore most impair the oxygen-carrying capacity of the blood.
DISCUSSION
Limited information is available on the pharmacokinetics of methylene blue in man. DiSanto and Wagner ll administered 10 mg of methylene blue orally to normal human subjects and measured the urinary excretion of methylene blue and leucomethylene blue. The excretion occurred over a five-day period with 53070-74070 of the administered dose being recovered in the urine.
As the surgical procedures during which the present data was collected were completed within two hours of the cessation of the methylene blue infusion, the terminal elimination phase could not be adequately defined. Characterisation of the methylene blue concentration time data by compartmental pharmacokinetic analysis was therefore limited. Apparent clearances based on the areas under the methylene blue concentration-time curve during the operation (clearance = dose/area) were very high (Table 2) , reflecting a rapid disappearance of methylene blue from the blood compartment into the tissues. The apparent volumes of distribution were also very large, consistent with a relocalisation of methylene blue from the plasma into the tissues. Extensive and rapid uptake of methylene blue by tissues in the rat after intravenous dosing has previously been demonstrated. 12 Anaesthesia and Intensive Care, Vol. 14, No. 4, November, 1986 Clinically, infusion of methylene blue in patients with an impaired ability to reduce methaemoglobin is likely to be of limited concern. Methaemoglobin reductase deficiency is rare, the patients presenting with congenital cyanosis and therefore likely to be found on preanaesthetic assessment. Although this deficiency would increase the production of methaemoglobin by methylene blue infusions, it is not known whether the possible increased production of methaemoglobin would be hazardous. Indeed, the reduced form of methylene blue (leucomethylene blue) is likely to catalyse the white blood cell diaphorase oxidoreductase pathway which is dependent on NADP generated by the oxidoreductase pathway hexose monophosphate shunt. 13, 14 This latter pathway accounts for less than 20% of the reductive capacity of blood and is that utilised in the paradoxical use of methylene blue in the treatment of methaemoglobinaemia.
